Journal of Viral Hepatitis

Article	Citations
Risk factors for the development of hepatocellular carcinoma (HCC) in chronic hepatitis B virus (HBV) infection: a systematic review and meta‐analysis	49
Distribution and clinical characteristics of patients with chronic hepatitis B virus infection in the grey zone	39
COVID‐19 and the Liver: Lessons Learnt from the EAST and the WEST, A Year Later	36
Global cascade of care for chronic hepatitis C virus infection: A systematic review and meta‐analysis	31
Durability of hepatitis B surface antigen seroclearance and subsequent risk for hepatocellular carcinoma: A meta‐analysis	31
SARS‐CoV‐2 infection in patients with a normal or abnormal liver	31
The case for simplifying and using absolute targets for viral hepatitis elimination goals	28
Risk of hepatocellular carcinoma in hepatitis B and D virus co‐infected patients: A systematic review and meta‐analysis of longitudinal studies	28
Clinical effects of NTCP‐inhibitor myrcludex B	27
Impact of direct‐acting antiviral regimens on mortality and morbidity outcomes in patients with chronic hepatitis c: Systematic review and meta‐analysis	27
The impact of the first, second and third waves of covid‐19 on hepatitis B and C testing in Ontario, Canada	26
Farnesoid X receptor agonist for the treatment of chronic hepatitis B: A safety study	23
Treatment for chronic hepatitis E virus infection: A systematic review and meta‐analysis	23
Hepatitis C treatment in a co‐located mental health and alcohol and drug service using a nurse‐led model of care	22
Real world SOF/VEL/VOX retreatment outcomes and viral resistance analysis for HCV patients with prior failure to DAA therapy	20
Effectiveness and Renal Safety of Tenofovir Alafenamide Fumarate among Chronic Hepatitis B Patients: Real‐World Study	20
What drives the dynamics of HBV RNA during treatment?	18
Global incidence and mortality of hepatitis B and hepatitis C acute infections, cirrhosis and hepatocellular carcinoma from 2010 to 2019	17
The effects of hepatitis B virus infection on natural and IVF pregnancy: A meta‐analysis study	17
Updated epidemiology of hepatitis C virus infections and implications for hepatitis C virus elimination in Germany	17
Baseline HBV‐DNA load plus AST/ALT ratio predicts prognosis of HBV‐related hepatocellular carcinoma after hepatectomy: A multicentre study	16
Effect of tenofovir alafenamide vs. tenofovir disoproxil fumarate on hepatocellular carcinoma risk in chronic hepatitis B	16
The Delta Delta: Gaps in screening and patient assessment for hepatitis D virus infection	16
Non‐invasive assessment of fibrosis regression and portal hypertension in patients with advanced chronic hepatitis C virus (HCV)‐associated liver disease and sustained virologic response (SVR): 3 year	15
The impact of point‐of‐care hepatitis C testing in needle and syringe exchange programs on linkage to care and treatment uptake among people who inject drugs: An Australian pilot study	15

Acute Delta Hepatitis in Italy spanning three decades (1991–2019): Evidence for the effectiveness of the hepatitis B vaccination campaign	15
Prevalence of hepatitis E infection among adults with concurrent chronic liver disease	15
Global prevalence of occult hepatitis B: A systematic review and meta‐analysis	15
Development and validation of a hepatitis B‐specific health‐related quality‐of‐life instrument: CLDQ‐HBV	15
Mean HBsAg decline at week 24 of PEG‐IFN‐based treatment predicts subsequent rate of HBsAg clearance — suggesting a valuable endpoint for early development HBV trials	15
The impact of DAA‐mediated HCV eradication on CD4+ and CD8+ T lymphocyte trajectories in HIV/HCV coinfected patients: Data from the ICONA Foundation Cohort	14
Removal of medicaid restrictions were associated with increased hepatitis C virus treatment rates, but disparities persist	14
Point‐of‐care hepatitis C testing and treatment strategy for people attending harm reduction and addiction centres for hepatitis C elimination	14
Anti‐HBc‐nonreactive occult hepatitis B infections with HBV genotypes B and C in vaccinated immunocompetent adults	14
Global prevalence and phylogeny of hepatitis B virus (HBV) drug and vaccine resistance mutations	14
Persistent Hepatitis E virus infection across England and Wales 2009‐2017: Demography, virology and outcomes	14
Health service utilization and experiences of stigma amongst people who inject drugs in Melbourne, Australia	13
Impact of maternal infection with hepatitis B virus on pregnancy complications and neonatal outcomes for women undergoing assisted reproductive technology treatment: A population‐based study	13
Evaluating the prevalence of Hepatitis E virus infection in a large cohort of European blood donors, 2015–2018	13
The role of hepatitis B virus core‐related antigen in predicting hepatitis B virus relapse after cessation of entecavir in hepatitis B e antigen‐negative patients	13
The impact of direct‐acting antivirals on hepatitis C viraemia among people who inject drugs in England; real‐world data 2011–2018	13
Efficacy of entecavir versus tenofovir in preventing hepatocellular carcinoma in patients with chronic hepatitis B with maintained virologic response	13
Factors affecting long‐term changes of liver stiffness in direct‐acting anti‐hepatitis C virus therapy: A multicentre prospective study	13
The ‘Viennese epidemic’ of acute HCV in the era of direct‐acting antivirals	12
Only partial improvement in health‐related quality of life after treatment of chronic hepatitis C virus infection with direct acting antivirals in a real‐world setting—results from the German Hepatiti	12
Benefit of transaminase elevations in establishing functional cure of HBV infection during nap‐based combination therapy	12
Estimating the attributable fraction of cirrhosis and hepatocellular carcinoma due to hepatitis B and C	12
Positive predictive value of sustained virologic response 4 weeks posttreatment for achieving sustained virologic response 12 weeks posttreatment in patients receiving glecaprevir/pibrentasvir in Phas	12
Cost‐effectiveness of screening and treatment using direct‐acting antivirals for chronic Hepatitis C virus in a primary care setting in Karachi, Pakistan	11
Analytical validation of hepatitis B core‐related antigen (HBcrAg) using dried blood spots (DBS)	11
Chronic hepatitis D—What is changing?	11
Viral hepatitis C pandemic: Challenges and threats to its elimination	11
Hepatitis A occurrence and outbreaks in Europe over the past two decades: A systematic review	11
Bile acid increase during bulevirtide treatment of hepatitis D is not associated with a decline in HDV RNA	11
Liver and cardiovascular mortality after hepatitis C virus eradication by DAA: Data from RESIST‐HCV cohort	11
Prognosis of hepatitis E infection in patients with chronic liver disease: A meta‐analysis	11
Direct antiviral agent treatment leads to rapid and significant fibrosis regression after HCV eradication	10
Role of peer support in a hepatitis C elimination programme	10
Cost‐effectiveness analysis of an active search to retrieve HCV patients lost to follow‐up (RELINK‐C strategy) and the impact of COVID‐19	10
Real‐world study on HBsAg loss of combination therapy in HBeAg‐negative chronic hepatitis B patients	10
Efficacy of an accelerated double‐dose hepatitis B vaccine regimen in patients with cirrhosis	10
The role of gut microbiota in hepatitis B disease progression and treatment	10
Long‐term benefits of interferon‐α therapy in children with HBeAg‐positive immune‐active chronic hepatitis B	10
Hepatitis C virus cure before hepatocellular carcinoma diagnosis is associated with improved survival	9
Patient‐reported outcomes of the Treatment and Prevention Study: A real‐world community‐based trial of direct‐acting antivirals for hepatitis C among people who inject drugs	9
Maternal chronic hepatitis B virus infection and the risk of preterm birth: A retrospective cohort analysis in Chinese women	9
Long‐term prognosis with or without nucleot(s)ide analogue therapy in hepatitis B virus–related decompensated cirrhosis	9
Progress towards the elimination of hepatitis B in children in Colombia: A novel two‐phase study approach	9
MiR‐155 regulates M2 polarization of hepatitis B virus‐infected tumour‐associated macrophages which in turn regulates the malignant progression of hepatocellular carcinoma	9
Hepatitis C testing and treatment uptake among young people who use opioids in New York City: A cross‐sectional study	9
Hepatitis C reinfection by treatment pathway among people who inject drugs in Tayside, Scotland	9
Increasing hepatitis C testing and linkage to care: Results of a testing campaign with incentives at primary care clinics in Melbourne, Australia	9
Epidemiology estimates of hepatitis D in individuals co‐infected with human immunodeficiency virus and hepatitis B virus, 2002–2018: A systematic review and meta‐analysis	9
Hepatitis E‐Associated Hospitalizations in the United States: 2010–2015 and 2015–2017	9
Insight into an acute hepatitis A outbreak in Indiana	8

Prevalence of hepatitis B virus amongst refugees, asylum seekers and internally displaced persons in low‐ and middle‐income countries: A systematic review	8
Hepatitis B surface antibody titres and hepatitis B reactivation with direct‐acting antiviral therapy for hepatitis C	8
Risk of drug‐induced liver injury in chronic hepatitis B and tuberculosis co‐infection: A systematic review and meta‐analysis	8
Viral hepatitis in pregnancy	8
Serum HBV RNA predicts HBeAg clearance and seroconversion in patients with chronic hepatitis B treated with nucleos(t)ide analogues	8
Rates of perfect self‐reported adherence to direct‐acting antiviral therapy and its correlates among people who inject drugs on medications for opioid use disorder: The PREVAIL study	8
Impact of direct‐acting antiviral agents on liver function in patients with chronic hepatitis C virus infection	8
Dynamic evaluation of hepatocellular carcinoma prediction models in patients with chronic hepatitis B receiving nucleotide/nucleoside analogue treatment	8
Hepatitis C treatment outcomes among people who inject drugs accessing harm reduction settings in Kenya	8
Altered balance between collagen formation and degradation after successful direct‐acting antiviral therapy of chronic hepatitis C	8
Epidemiology of hepatitis D virus infection in Europe: Is it vanishing?	8
Hepatitis B virus–induced hepatocarcinogenesis: A virological and oncological perspective	8
Antiviral treatment for hepatitis C is associated with a reduced risk of atherosclerotic cardiovascular outcomes: A systematic review and meta‐analysis	8
VirA+EmiC project: Evaluating real‐world effectiveness and sustainability of integrated routine opportunistic hepatitis B and C testing in a large urban emergency department	8
Resistance‐associated substitutions after sofosbuvir/velpatasvir/voxilaprevir triple therapy failure	8
RETRACTED: Infectivity of hepatitis B virus (HBV) surface antigen (HBsAg) positive plasma with undetectable HBV‐DNA: Can HBsAg screening be discontinued in Egyptian blood donors?	8
Global evolutionary analysis of chronic hepatitis C patients revealed significant effect of baseline viral resistance, including novel non‐target sites, for DAA‐based treatment and retreatment outcome	8
Retreatment for hepatitis C virus direct‐acting antiviral therapy virological failure in primary and tertiary settings: The REACH‐C cohort	8
Correlates of chronic hepatitis B virus infection in the general adult population of China: Systematic review and meta‐analysis	8
A cross‐sectional study of hepatitis C prevalence and correlates among persons who inject drugs in rural and non‐rural communities	7
Impact of COVID‐19 lockdown restrictions on hepatitis C testing in Australian primary care services providing care for people who inject drugs	7
Inhibition of hepatitis E virus replication by zinc‐finger antiviral Protein synergizes with IFN‐β	7
Provider‐related barriers and enablers to the provision of hepatitis C treatment by general practitioners in Scotland: A behaviour change analysis	7
Cure everyone and vaccinate the rest: The patient perspective on future hepatitis B treatment	7
Distinct Hepatitis B and HIV co‐infected populations in Canada	7
Hepatitis B surface antigen kinetics after discontinuation of and retreatment with oral antivirals in non‐cirrhotic HBeAg‐positive chronic hepatitis B	7
Hepatitis B e antigen loss in adults and children with chronic hepatitis B living in North America: A prospective cohort study	7
Significance of serum HBV RNA in non‐cirrhotic HBeAg‐negative chronic hepatitis B patients who discontinue effective antiviral therapy	7
Hepatitis E prevalence and infection in solid‐organ transplant recipients in the United States	7
Long‐term renal safety between patients with chronic hepatitis B receiving tenofovir vs. entecavir therapy: A multicenter study	7
The 48‐week safety and therapeutic effects of tenofovir alafenamide in hbv‐related acute‐on‐chronic liver failure: A prospective cohort study	7
Changes in the estimated renal function after hepatitis C virus eradication with direct‐acting antiviral agents: Impact of changes in skeletal muscle mass	7
Contextual and individual factors associated with knowledge, awareness and attitude on liver diseases: A large‐scale Asian study	7
Hepatitis C hospitalizations in Spain and impact of new curative antiviral therapies	7
Decreasing prevalence and stagnating incidence of Hepatitis C‐co‐infection among a cohort of HIV‐1‐positive patients, with a majority of men who have sex with men, in Germany, 1996–2019	7
Secreted hepatitis B virus splice variants differ by HBV genotype and across phases of chronic hepatitis B infection	7
Shear wave elastography: How well does it perform in chronic hepatitis D virus infection?	7
Internet‐guided HCV‐RNA testing: A promising tool to achieve hepatitis C micro‐elimination among men who have sex with men	7
Hepatitis C prevalence and elimination planning in Pakistan, a bottom‐up approach accounting for provincial variation	7
Challenges of hepatitis B treatment in rural Sub‐Saharan Africa: Treatment initiation and outcomes from a public hospital‐based clinic in Kono, Sierra Leone	6
Effects of on‐treatment ALT flares on serum HBsAg and HBV RNA in patients with chronic HBV infection	6
Improvement of chronic HCV infection‐related depression, anxiety, and neurocognitive performance in persons achieving SVR‐12: A real‐world cohort study	6
Kinetics of serum O‐glycosylated M‐hepatitis B surface antigen with hepatocellular carcinoma history and nucleos(t)ide analogue therapy in hepatitis B patients	6
Cost‐effectiveness analysis of sofosbuvir and velpatasvir in chronic hepatitis C patients with decompensated cirrhosis	6
Bulevirtide‐based treatment strategies for chronic hepatitis delta: A review	6
Hepatitis C related cognitive impairment: Impact of viral and host factors and response to therapy	6
Hepatitis C care cascade before and during the direct‐acting antiviral eras in New South Wales, Australia: A population‐based linkage study	6
Clinical and patient‐reported outcome profile of patients with hepatitis B viral infection from the Global Liver Registry™	6
Evolution of estimated glomerular filtration rate in human immunodeficiency virus and hepatitis C virus‐coinfected patients receiving sofosbuvir‐based direct‐acting antivirals and antiretroviral thera	6
Peg‐interferon alpha add‐on Tenofovir disoproxil fumarate achieved more HBsAg loss in HBeAg‐positive chronic hepatitis B naïve patients	6
Non‐invasive fibrosis markers for assessment of liver fibrosis in chronic hepatitis delta	6
Integration and the risk of liver cancer—Is there a real risk?	6
Association of hepatitis C infection and risk of kidney cancer: A systematic review and meta‐analysis of observational studies	6
Missed linkage to care for patients who screened positive for Hepatitis C in a tertiary care centre: Results of the Telepass project	6
HIV influences clustering and intracellular replication of hepatitis C virus	6
What facilitates hepatitis B and hepatitis C testing and the role of stigma among primary care patients in China?	6
Novel concepts on mechanisms underlying Hepatitis Delta virus persistence and related pathogenesis	6
Role of hepatitis B surface antibody in seroreversion of hepatitis B surface antigen in patients achieving hepatitis B surface antigen loss with pegylated interferon‐based therapy	6
The changing characteristics of patients infected with chronic hepatitis C virus from 2014 to 2019: Real‐world data from the German Hepatitis C‐Registry (DHC‐R)	6
Validation of the HCC‐RESCUE score to predict hepatocellular carcinoma risk in Caucasian chronic hepatitis B patients under entecavir or tenofovir therapy	6
Tenofovir versus entecavir for tertiary prevention of hepatocellular carcinoma in chronic hepatitis B infection after curative therapy: A systematic review and meta‐analysis	6
Why do patients with chronic hepatitis C drink alcohol? An examination of pain, depression and drinking motives	6
Factors linked to hepatocellular carcinoma development beyond 10 years after viral eradication in patients with hepatitis C virus	6
Temporal and geographic spreading of hepatitis B virus genotype A (HBV‐A) in Brazil and the Americas	6
Evaluating the renal safety of tenofovir disoproxil fumarate in hepatitis B patients without chronic kidney disease	6
External validation of CAGE‐B and SAGE‐B scores for Asian chronic hepatitis B patients with well‐controlled viremia by antivirals	6
No influence of hepatic steatosis on the 3‐year outcomes of patients with quiescent chronic hepatitis B	6
Progress on the elimination of viral hepatitis in Zimbabwe: A review of the policies, strategies and challenges	6
Hepatitis delta virus: Disease assessment and stratification	6
Influencing factors and necessity of post‐vaccination serologic testing follow‐up for HBsAg‐positive mothers and their infants: A 5‐year prospective study in Zhejiang Province, China (2016–2020)	6
Clinical significance of quantitative e antigen in a cohort of hepatitis B virus‐infected children and adults in North America	6
Adherence to pregnancy hepatitis B care guidelines in women and infants in the United States and evaluation of two interventions to improve care: A multicentre hospital‐based study	6
Circulating cell‐free DNA species affect the risk of hepatocellular carcinoma in treated chronic hepatitis B patients	5
HCV hotline facilitates Hepatitis C elimination during the COVID‐19 pandemic	5
Clinical impact of hepatic steatosis on chronic hepatitis B patients in Asia: A systematic review and meta‐analysis	5
Monkeypox outbreak as an opportunity to identify new cases of HCV infection in limited resource settings	5
External validation of hepatocellular carcinoma risk scores in patients with chronic hepatitis B virus infection in China	5
Risk factors for liver‐related and non‐liver‐related mortality following a sustained virological response after direct‐acting antiviral treatment for hepatitis C virus infection in a real‐world cohort	5
Determining the therapeutic range for ribavirin in transplant recipients with chronic hepatitis E virus infection	5
Neuropsychological effects of direct‐acting antiviral treatment for Hepatitis C virus subjects: A systematic review	5

Evolutionary seroepidemiology of viral hepatitis and the gap in hepatitis C care cascades among uraemic patients receiving haemodialysis in Taiwan—the Formosa‐Like Group	5
A population‐based study of reported hepatitis C diagnoses from 1998 to 2018 in immigrants and nonimmigrants in Quebec, Canada	5
Epidemiology and treatment of hepatitis E in the liver transplantation setting: A literature review	5
Randomized clinical trial: Direct‐acting antivirals as treatment for hepatitis C in people who inject drugs: Delivered in needle and syringe programs via directly observed therapy versus fortnightly c	5
Follow‐up evaluation of patients with liver test abnormalities detected during SARS‐CoV2 infection	5
Hepatitis D‐associated hospitalizations in the United States: 2010–2018	5
Hepatitis C virus care cascade in persons experiencing homelessness in the United States in the era of direct‐acting antiviral agents: A scoping review	5
High rates of sustained virological response despite premature discontinuation of directly acting antivirals in HCV‐infected patients treated in a real‐life setting	5
Temporal evolution and global spread of hepatitis B virus genotype G	5
Clinical and occupational health management of healthcare workers living with chronic hepatitis B: UK policy and international comparisons	5
Hepatitis C active viremia over time in an ED‐based testing programme: Impact, disparities and surveillance tool	5
Variceal recurrence 4 years post endoscopic band ligation in hepatitis C patients who achieved sustained virological response with oral direct‐acting antiviral therapy	5
Hepatic steatosis and metabolic risk factors among patients with chronic hepatitis B: The multicentre, prospective CAP‐Asia study	5
Extrahepatic carcinogenicity of oral nucleos(t)ide analogues in chronic hepatitis B carriers: A 35,000‐Korean outcome study	5
The cost‐effectiveness of case‐finding strategies for achieving hepatitis C elimination among men who have sex with men in the UK	5
Early clinical efficacy of pegylated interferon treatment in patients with different phases of chronic HBV infection: A real‐world analysis	5
Serum PreS1 and HBsAg ratio reflects liver fibrosis and predicts the development of hepatocellular carcinoma in chronic hepatitis B patients	5
Effectiveness of direct acting antiviral agents for hepatitis C virus related recurrent hepatocellular carcinoma patients who had multiple courses of recurrence	5
Integrated supervised consumption services and hepatitis C testing and treatment among people who inject drugs in Toronto, Canada: A cross‐sectional analysis	5
A transient early HBV‐DNA increase during PEG‐IFNα therapy of hepatitis D indicates loss of infected cells and is associated with HDV‐RNA and HBsAg reduction	5
Beyond bulevirtide: Alternative therapeutic options for the management of hepatitis delta virus	4
Incidence of post‐transplant hepatitis B virus reactivation with the use of kidneys from donors with resolved hepatitis B virus infection	4
Assessment of subclinical effects of Hepatitis E virus infection in the United States	4
Uptake of interferon‐free DAA therapy among HCV‐infected decompensated cirrhosis patients and evidence for decreased mortality	4
Direct‐acting antivirals reduce the risk of tumour progression of hepatocellular carcinoma after curative treatment	4
International multicenter validation of GES score for HCC risk stratification in chronic hepatitis C patients	4
Migrants and hepatitis: A tale of two worlds	4
Chronic hepatitis C virus infections in Switzerland in 2020: Lower than expected and suggesting achievement of WHO elimination targets	4
Closing the hepatitis C treatment gap: United States strategies to improve retention in care	4
Cost‐effectiveness of treating all hepatitis B–positive individuals in the United States	4
Investigating rates and risk factors for hepatitis C virus reinfection in people receiving antiviral treatment in England	4
Assessing risk scores for predicting hepatocellular carcinoma in Thai patients with chronic hepatitis B	4
Universal versus targeted screening for HCV infection in pregnancy in a diverse, multi‐ethnic population: Universal screening is more comprehensive	4
Silent HDV epidemics culminates in high levels of liver cirrhosis in endemic region despite 20 years of HBV vaccination	4
Hepatitis C antibody prevalence, correlates and barriers to care among people who inject drugs in Central California	4
A declaration from people living with hepatitis B: A call for a whole person approach	4
Posttreatment nonalcoholic fatty liver disease fibrosis scores for predicting liver‐related complications in patients with chronic hepatitis C receiving direct‐acting antiviral agents	4
Liver fibrosis scores and risk of liver‐related mortality in young adults with chronic hepatitis B: A cohort study	4
TRPM2 regulates autophagy to participate in hepatitis B virus replication	4
Associated screening for HCV and SARS‐Cov2 infection in an urban area of Southern Italy: A cohort study	4
Reversibility of acute‐on‐chronic liver failure syndrome in hepatitis B virus‐infected patients with and without prior decompensation	4
Hepatocellular carcinoma and hepatitis C virus treatments: The bold and the beautiful	4
Signal transducer and activator of transcription 3 cooperates with androgen receptor/cell cycle‐related kinase signalling pathway in the progression of hepatitis B virus infection and gender differenc	4
More intensive hepatitis C virus care models promote adherence among people who inject drugs with active drug use: The PREVAIL study	4
Hepatitis C virus infection mortality trends according to three definitions with special concern for the baby boomer birth cohort	4
Impact of treatment with direct‐acting antivirals on inflammatory markers and autoantibodies in HIV/HCV co‐infected individuals	4
Hepatitis C virus: Testing rate and attrition at linkage to specialized care, Catalonia, Spain 2011‐2016	4
Early virologic relapse predicts alanine aminotransferase flares after nucleos(t)ide analogue withdrawal in patients with chronic hepatitis B	4
Thyroid dysfunction incidence and risk factors in Chinese chronic hepatitis B patients treated with pegylated interferon alpha: A long‐term follow‐up study	4
Mortality in relation to hepatitis B virus (HBV) infection status among HIV‐HBV co‐infected patients in sub‐Saharan Africa after immediate initiation of antiretroviral therapy	4
The impact of hepatitis flare on HBeAg loss was effective mainly in the first year of Nucleot(s)ide therapy in chronic hepatitis B	4
Excellent hepatitis C virus cure rates despite increasing complexity of people who use drugs: Integrated‐Test‐stage Treat study final outcomes	4
The immune landscape in hepatitis delta virus infection—Still an open field	4
A randomized phase 1b trial of the active site polymerase inhibitor nucleotide ATI‐2173 in patients with chronic hepatitis B virus infection	4
Progress towards micro‐elimination of hepatitis C in the custodial setting	4
Derivation and validation of prognostic models for predicting survival outcomes in Acute‐on‐chronic liver failure patients	4
Delta hepatitis epidemiology and the global burden of disease	4
Dynamic risk assessment for hepatocellular carcinoma in patients with chronic hepatitis C	4
The elimination of hepatitis D as a public health problem: Needs and challenges	4
Symptoms and functioning improve after chronic hepatitis C cure as assessed by the Memorial Symptom Assessment Scale and PROMIS measures	4
The cost‐effectiveness of hepatitis C virus elimination in low‐ and middle‐income countries	4
A novel non‐invasive model for the prediction of advanced liver fibrosis in chronic hepatitis B patients with NAFLD	4
Persistent chronic immune activation in HIV/HBV‐coinfected patients after antiretroviral therapy	4
Sustained and cumulative impact of an electronic medical record‐based alert on a hepatitis C birth cohort screening programme	4
A modelling analysis of financial incentives for hepatitis C testing and treatment uptake delivered through a community‐based testing campaign	4
Large‐scale screening is not useful for identifying individuals with hepatitis B or C virus infection: A prospective Swiss study	4
Serum α‐fetoprotein level at treatment completion is a useful predictor of hepatocellular carcinoma occurrence more than one year after hepatitis C virus eradication by direct‐acting antiviral treatme	4
Improvement in cognitive impairment following a 12‐week aerobic exercise intervention in individuals with non‐cirrhotic chronic hepatitis C	4
Recombinant human thrombopoietin increases platelet count in severe thrombocytopenic patients with hepatitis B‐related cirrhosis: Multicentre real‐world observational study	4
A risk scoring system to predict clinical events in chronic hepatitis B virus infection: A nationwide cohort study	4
Electronic nose versus quadrupole mass spectrometry for identifying viral hepatitis C patients	4
Severe impairment of patient‐reported outcomes in patients with chronic hepatitis C virus infection seen in real‐world practices across the world: Data from the global liver regi	4
Risk assessment of hepatocellular carcinoma and liver‐related events using ultrasonography and transient elastography in patients with chronic hepatitis B	4
The changing epidemiology of delta hepatitis in Türkiye over three decades: A systematic review	3
	3
Abnormal liver function tests and coronavirus disease 2019: A close relationship	3
Genome‐wide methylation profiling of HCV pathogenesis to develop diabetes and diabetic complications	3
Persistence of immunity against hepatitis A in Brazilian children vaccinated with a single dose of inactivated virus vaccine	3
Efficacy and safety of direct‐acting antiviral therapy for hepatitis C virus in elderly patients (≥65 years old): A systematic review and meta‐analysis	3
Hepatitis C virus eradication ameliorates the prognosis of advanced hepatocellular carcinoma treated with sorafenib	3
Variability in molecular characteristics of Hepatitis E virus quasispecies could modify viral surface properties and transmission	3
Low incidence and prevalence of hepatitis C in two cohorts of HIV pre‐exposure prophylaxis adherence interventions in men who have sex with men in Southern California	3
Knowledge, perception and expectation of management of hepatitis B infection among pregnant hepatitis B carriers in Hong Kong	3
HBV pgRNA profiles in Chinese HIV/HBV coinfected patients under pre‐ and posttreatment: a multicentre observational cohort study	3
Psychiatrists can treat hepatitis C	3
Post‐HCV cure self‐reported changes in physical activity, eating behaviours, and fatigue in people living with HIV (ANRS CO13 HEPAVIH)	3
Implementation of a re‐linkage to care strategy in patients with chronic hepatitis C who were lost to follow‐up in Latin America	3
Reduction in hepatitis C‐related hospitalizations after the implementation of the Strategic Plan for Tackling Hepatitis C in the Spanish National Health System: regional level differences	3
Adenovirus vector encoding TPPII ignites HBV‐specific CTL response by activating autophagy in CD8+ T cell	3
Assessing the hepatitis C epidemiology in Switzerland: It’s not that trivial	3
Safety, pharmacokinetics and antiviral activity of ABI‐H2158, a hepatitis B virus core inhibitor: A randomized, placebo‐controlled phase 1 study	3
Factors influencing compliance with Hepatitis C treatment in patients transitioning from prison to community—A summary scoping review	3
Patient‐reported experiences with direct acting antiviral therapy in an integrated model of hepatitis C care in homeless shelters	3
Early HBV RNA kinetics under NA treatment may reveal new insights into HBV RNA dynamics and NA mode of action‐more detailed kinetic studies are needed	3
Death certificates compared to SEER‐Medicare data for surveillance of liver cancer mortality due to hepatitis B or hepatitis C infection	3